Literature DB >> 9276728

Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes.

K W Wucherpfennig1, I Catz, S Hausmann, J L Strominger, L Steinman, K G Warren.   

Abstract

Myelin basic protein (MBP) may be an important autoantigen in multiple sclerosis (MS), with the MBP(82-100) region being immunodominant for T cells and autoantibodies. The structural requirements for autoantibody recognition were compared to those previously defined for MBP-specific T cell clones. MBP autoantibodies were affinity-purified from central nervous system lesions of 11/12 postmortem cases studied. The MBP(83-97) peptide was immunodominant in all 11 cases since it inhibited autoantibody binding to MBP > 95%. Residues contributing to autoantibody binding were located in a 10-amino acid segment (V86-T95) that also contained the MHC/T cell receptor contact residues of the T cell epitope. In the epitope center, the same residues were important for antibody binding and T cell recognition. Based on the antibody-binding motif, microbial peptides were identified that were bound by purified autoantibodies. Autoantibody binding of microbial peptides required sequence identity at four or five contiguous residues in the epitope center. Microbial peptides previously found to activate T cell clones did not have such obvious homology to MBP since sequence identity was not required at MHC contacts. The similar fine specificity of B cells and T cells may be useful for tolerance induction to MBP in MS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276728      PMCID: PMC508286          DOI: 10.1172/JCI119622

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

Review 1.  Lymphocyte responses and cytokines.

Authors:  W E Paul; R A Seder
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

2.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide.

Authors:  L J Stern; J H Brown; T S Jardetzky; J C Gorga; R G Urban; J L Strominger; D C Wiley
Journal:  Nature       Date:  1994-03-17       Impact factor: 49.962

3.  Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis.

Authors:  K G Warren; I Catz
Journal:  J Neuroimmunol       Date:  1993-03       Impact factor: 3.478

4.  The involvement of specific anti myelin basic protein antibody-forming cells in multiple sclerosis immunopathology.

Authors:  K Gerritse; C Deen; M Fasbender; R Ravid; W Boersma; E Claassen
Journal:  J Neuroimmunol       Date:  1994-01       Impact factor: 3.478

5.  Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy.

Authors:  A Gaur; B Wiers; A Liu; J Rothbard; C G Fathman
Journal:  Science       Date:  1992-11-27       Impact factor: 47.728

6.  Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis.

Authors:  K G Warren; I Catz; E Johnson; B Mielke
Journal:  Ann Neurol       Date:  1994-03       Impact factor: 10.422

7.  Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid.

Authors:  K G Warren; I Catz
Journal:  J Neurol Sci       Date:  1994-01       Impact factor: 3.181

8.  Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide.

Authors:  K W Wucherpfennig; J Zhang; C Witek; M Matsui; Y Modabber; K Ota; D A Hafler
Journal:  J Immunol       Date:  1994-06-01       Impact factor: 5.422

9.  B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells.

Authors:  S Nonoyama; D Hollenbaugh; A Aruffo; J A Ledbetter; H D Ochs
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

10.  Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones.

Authors:  K W Wucherpfennig; A Sette; S Southwood; C Oseroff; M Matsui; J L Strominger; D A Hafler
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  40 in total

Review 1.  Antigen specific immunotherapy of multiple sclerosis.

Authors:  L Steinman; P Conlon
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

Review 2.  Multiple sclerosis.

Authors:  Alyssa Nylander; David A Hafler
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 3.  B-cells and humoral immunity in multiple sclerosis. Implications for therapy.

Authors:  Sangjin Oh; Cornelia Cudrici; Takahiro Ito; Horea Rus
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 4.  Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet.

Authors:  Lawrence Steinman
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

5.  Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis.

Authors:  S Shimoda; J Van de Water; A Ansari; M Nakamura; H Ishibashi; R L Coppel; J Lake; E B Keeffe; T E Roche; M E Gershwin
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

Review 6.  The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

Authors:  Andrew P Robinson; Christopher T Harp; Avertano Noronha; Stephen D Miller
Journal:  Handb Clin Neurol       Date:  2014

7.  Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope.

Authors:  Abdiwahab A Musse; Joan M Boggs; George Harauz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-09       Impact factor: 11.205

8.  A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.

Authors:  Carlos Riveros; Drew Mellor; Kaushal S Gandhi; Fiona C McKay; Mathew B Cox; Regina Berretta; S Yahya Vaezpour; Mario Inostroza-Ponta; Simon A Broadley; Robert N Heard; Stephen Vucic; Graeme J Stewart; David W Williams; Rodney J Scott; Jeanette Lechner-Scott; David R Booth; Pablo Moscato
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

9.  Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS.

Authors:  Doris Lambracht-Washington; Kevin C O'Connor; Elizabeth M Cameron; Andrea Jowdry; E Sally Ward; Elliot Frohman; Michael K Racke; Nancy L Monson
Journal:  J Neuroimmunol       Date:  2007-04-23       Impact factor: 3.478

Review 10.  Myelin Basic Protein Citrullination in Multiple Sclerosis: A Potential Therapeutic Target for the Pathology.

Authors:  Lei Yang; Dewei Tan; Hua Piao
Journal:  Neurochem Res       Date:  2016-04-21       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.